Caitong International Asset Management’s AbCellera Biologics ABCL Stock Holding History

Caitong International Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$327K	Buy	41,632 +41,042	+6,956%	+$201K	0.04%	315
2026 Q1	$2.06K	Sell	590 -3,492	-86%	-$12.6K	﹤0.01%	1234
2025 Q4	$14K	Buy	+4,082	New	+$18.2K	﹤0.01%	1075
2025 Q3	–	Sell	-10,127	Closed	-$34.7K	–	1876
2025 Q2	$34.7K	Buy	+10,127	New	+$25.2K	0.02%	354

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Caitong International Asset Management's ABCL Position: Q2 2026 in Review

Caitong International Asset Management increased its AbCellera Biologics (ABCL) stake by 6,956% in Q2 2026, buying an estimated $201K and bringing the position to 41,632 shares worth $327K. The position accounts for 0.04% of the portfolio, ranked #315.

Caitong International Asset Management first reported a position in ABCL in Q2 2025 and has held it in 4 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Caitong International Asset Management held 41,632 shares of AbCellera Biologics worth $327K as of Q2 2026.
Caitong International Asset Management bought 41,042 AbCellera Biologics shares in Q2 2026, an estimated $201K.
AbCellera Biologics made up 0.04% of Caitong International Asset Management's portfolio in Q2 2026, its #315 holding.
Caitong International Asset Management first reported a position in AbCellera Biologics in Q2 2025 and has held it in 4 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.